...
首页> 外文期刊>Scandinavian journal of infectious diseases. >Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study.
【24h】

Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study.

机译:一项回顾性队列研究表明,对于未接受抗逆转录病毒治疗的HIV感染患者,沙奎那韦硬凝胶不能充分抑制病毒载量。

获取原文
获取原文并翻译 | 示例

摘要

Protease inhibitors are important components in anti-retroviral regimens. In this retrospective study 29 HIV-infected patients treated with a regimen of zidovudine, lamivudine and saquinavir hard gel in 1 centre in Denmark were compared with 58 patients treated with zidovudine, lamivudine and ritonavir or indinavir followed at 5 other centres in Scandinavia. All patients were naive to anti-retroviral therapy prior to institution of the actual anti-retroviral regimen and were followed for a median of 1.3 and 1.4 y respectively. The 2 groups did not differ significantly with respect to age, gender, route of infection, ethnic background, viral load, CD4 count, AIDS at baseline or frequency of clinical controls. Six and 12 months after initiating anti-retroviral therapy, 31% and 34% of the patients on the saquinavir regimen obtained HIV-RNA < or = 500 compared with 76% and 73% in the control group (p < 0.001). In contrast to viral load, the increase in CD4 count did not differ significantly between the 2 groups. In conclusion, we found that with respect to suppression of viral load a regimen of saquinavir, zidovudine and lamivudine seemed to be inferior to a regimen of zidovudine, lamivudine and ritonavir or indinavir.
机译:蛋白酶抑制剂是抗逆转录病毒疗法中的重要组成部分。在这项回顾性研究中,对丹麦1个中心接受齐多夫定,拉米夫定和沙奎那韦硬凝胶治疗的29例HIV感染患者与58例接受齐多夫定,拉米夫定和利托那韦或茚地那韦治疗的患者进行了比较,随后在斯堪的纳维亚的其他5个中心进行了比较。在实施实际的抗逆转录病毒治疗方案之前,所有患者均未接受过抗逆转录病毒治疗,其中位时间分别为1.3年和1.4年。两组在年龄,性别,感染途径,种族背景,病毒载量,CD4计数,基线或临床控制频率的AIDS方面无显着差异。在开始抗逆转录病毒治疗后的六个月和十二个月,接受沙奎那韦治疗的患者中分别有31%和34%的患者获得HIV-RNA <或= 500,而对照组为76%和73%(p <0.001)。与病毒载量相比,两组之间CD4计数的增加没有显着差异。总之,我们发现就抑制病毒载量而言,沙奎那韦,齐多夫定和拉米夫定的治疗方案似乎逊于齐多夫定,拉米夫定和利托那韦或茚地那韦的治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号